News|Videos|June 19, 2024
Integrating GPRC5D-Targeting Bispecifics for Relapsed/Refractory MM
Beth Faiman, PhD, MSN, explores how a GPRC5D-targeting bispecific antibody can benefit patients with relapsed/refractory multiple myeloma.
Advertisement
Episodes in this series
Advertisement
Related to this article
Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.
Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.
Beth Faiman, PhD, and Sikander Ailawadhi, MD, discuss clinic workflows, safety checks, and at-home dosing potential for on-body isatuximab.
Erika Hamilton, MD, breaks down liver monitoring, diarrhea, creatinine shifts, and oral adherence with maintenance tucatinib in HER2+ MBC.
ABUS matched handheld ultrasound on cancer detection in women with dense breasts while lowering recall and short-interval follow-up rates.
Long-term QUILT-3.032 data in BCG-unresponsive NMIBC with CIS show durable responses for some patients and a long, surveillance-heavy course.
The approval in stage II/III MSI-H/dMMR rectal cancer rests on AZUR-1, in which 71% of patients needed no treatment beyond dostarlimab.
Dr. Andrew Pecora on leading the first IV oncolytic virus trial, building a top-50 cancer center, and using AI to fix the cost of cancer care.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Grants Accelerated Approval to Dostarlimab in dMMR Rectal Cancer
2
Tucatinib Maintenance for HER2+ Breast Cancer: What Nurses, PAs Should Know
3
Anktiva Plus BCG: 84% of Responders Cystectomy-Free at 3 Years
4
How AI Could Ease the Cost Crisis in Cancer Care
5